
BusinessReported
Novartis Shares Fall 9% After Setbacks in Three Drug Trials
Shares of the Swiss pharmaceutical company dropped sharply on Tuesday after disappointing results from its del-desiran drug trial, according to a CNBC report.
· 1 min read

Shares of the Swiss pharmaceutical company dropped sharply on Tuesday after disappointing results from its del-desiran drug trial, according to a CNBC report.

The pharmaceutical company's stock dropped sharply Tuesday following disappointing results from trials including its del-desiran drug.